局部进展期胃癌新辅助治疗前后Node-RADS的预后与诊断价值
回顾性分析131例接受新辅助化疗后手术的局部进展期胃癌患者,由放射科医师基于化疗前后CT重新评估Node-RADS评分,以≥3分为阳性。治疗后Node-RADS≥3分在多因素分析中与总生存显著相关(HR=3.60),治疗前诊断淋巴结转移AUC为0.786、敏感度86.7%、特异度53.7%,治疗后AUC为0.717、敏感度41.1%、特异度97.6%。
要点
- 治疗后Node-RADS≥3分是多因素分析中与总生存相关的独立预后因素(HR=3.60)。
- 治疗前Node-RADS≥3分诊断淋巴结转移敏感度86.7%、特异度53.7%,AUC 0.786。
- 治疗后Node-RADS≥3分诊断敏感度降至41.1%、特异度升至97.6%,AUC 0.717。
核心结论
- Node-RADS评分尤其是新辅助化疗后评分,是预测局部进展期胃癌残留淋巴结转移和生存的有效预后工具。
- 作者认为该评分系统可能有助于治疗后的临床决策。
研究设计与样本
- 回顾性研究,纳入131例诊断为局部进展期胃癌并接受新辅助化疗后手术的患者。
- 由放射科医师基于新辅助化疗前和治疗后的CT图像重新评估Node-RADS评分,以≥3分为阳性。
- 采用Kaplan-Meier曲线和Cox回归分析进行生存分析。
诊断标准与关键数值
- 治疗前以Node-RADS≥3分为阳性阈值,诊断淋巴结转移AUC 0.786、敏感度86.7%、特异度53.7%。
- 治疗后以Node-RADS≥3分为阳性阈值,诊断淋巴结转移AUC 0.717、敏感度41.1%、特异度97.6%。
- 治疗前Node-RADS≥3分仅单因素分析与总生存相关(HR=2.20,95%CI 1.12-4.34,P=0.023),与无病生存无关联。
- 治疗后Node-RADS≥3分与总生存的单因素分析HR=1.21(95%CI 1.00-1.45,P=0.049)、多因素分析HR=3.60(95%CI 1.05-12.3,P=0.041);与无病生存仅单因素分析显著(HR=1.96,95%CI 1.16-3.30,P=0.012)。
临床应用与阅片要点
- 治疗后Node-RADS≥3分对残留淋巴结转移诊断特异度97.6%,但敏感度仅41.1%。
- 治疗前Node-RADS≥3分对淋巴结转移诊断敏感度86.7%,但特异度仅53.7%。
- 随访期间61例(46.5%)死亡,68例(51.9%)出现疾病复发;中位总生存随访36.5个月(IQR 19.5-55.7),中位无病生存28.5个月(IQR 16.2-45.4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to evaluate the performance of the Node-RADS scoring system in predicting lymph node metastasis in patients with locally advanced gastric cancer(LAGC) before and after neoadjuvant chemotherapy(NAC), and to determine its prognostic value for overall survival(OS) and disease-free survival(DFS).
METHODS: Data from 131 patients diagnosed with LAGC who underwent NAC were retrospectively reviewed. All patients had undergone surgical treatment. The Node-RADS score was re-assessed by radiologists based on both pre- and post-NAC CT images. A Node-RADS score of ≥3 was considered positive, and its diagnostic value and prognostic impact were analyzed. Survival analyses were performed using Kaplan-Meier curves and Cox regression analysis.
RESULTS: In the pre-treatment period, a Node-RADS score ≥3 was significantly associated with overall survival (OS) only in the univariate analysis (HR = 2.20 [95 % CI:1.12-4.34],p = 0.023),with no association observed for DFS. In the post-treatment period, OS was significantly associated in both univariate and multivariate analyses (univariate HR = 1.21, [95 % CI:1.00-1.45], p = 0.049;multivariate HR = 3.60, [95 % CI:1.05-12.3], p = 0.041),while DFS was significant only in the univariate analysis(HR = 1.96 [95 % CI:1.16-3.30], p = 0.012).In terms of diagnostic accuracy, applying a Node-RADS ≥3 threshold achieved an AUC of 0.786, with 86.7 % sensitivity and 53.7 % specificity in the pre-treatment period, whereas in the post-treatment period it yielded an AUC of 0.717, with 41.1 % sensitivity and 97.6 % specificity. A total of 61(46.5 %) patients died, and 68(51.9 %) patients experienced disease recurrence during the follow-up period. Among 131 patients, the median follow-up duration OS was 36.5 months [IQR: 19.5-55.7], and the median DFS was 28.5 months [IQR: 16.2-45.4].
CONCLUSION: The Node-RADS score, particularly in the post-NAC period, is an effective prognostic tool for predicting residual lymph node metastases and survival in patients with LAGC. These findings suggest that the scoring system may aid in clinical decision-making after treatment.
引用
- Dilek O, Demirel E, Erisen KK, et al. Prognostic and diagnostic value of node-RADS before and after neoadjuvant therapy in locally advanced gastric cancer. Eur J Radiol. 2025. PMID: 41270706. doi:10.1016/j.ejrad.2025.112525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。